SMART-101 is under clinical development by Smart Immune and currently in Phase II for Refractory Acute Myeloid Leukemia.

SMART-101 is under clinical development by Smart Immune and currently in Phase II for Relapsed Acute Myeloid Leukemia.

EBBH-2024 is under clinical development by Essen Biotech and currently in Phase II for Diffuse Large B-Cell Lymphoma.

DVX-201 is under clinical development by Coeptis Therapeutics and currently in Phase I for Myelodysplastic Syndrome.

CYTO-102 is under clinical development by CytoImmune Therapeutics and currently in Phase I for Non-Small Cell Lung Cancer.

Zofin is under clinical development by ZEO ScientifiX and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Not Disclosed Neuroscience and Pain 2 is under clinical development by Evotec and currently in Phase I for Unspecified Neurologic Disorders.

Dexamethasone sodium phosphate is under clinical development by AVM Biotechnology and currently in Phase II for Metastatic Pancreatic Cancer.

BNT-162b1 is under clinical development by BioNTech and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

NVL-330 is under development for the treatment of non-small cell lung cancer. The drug candidate act by targeting HER2. It is administered by oral route in the form of tablet.

TB-006 is under clinical development by TrueBinding and currently in Phase II for Autism Spectrum Disorder (ASD).

ANS-014004 is under development for the treatment of solid tumor and non small cell lung cancer (NSCLC). The therapeutic candidate is administered through oral route as tablet formulation. It acts by ...